Ignite Creation Date:
2024-05-05 @ 10:45 PM
Last Modification Date:
2024-10-26 @ 10:23 AM
Study NCT ID:
NCT01171417
Status:
COMPLETED
Last Update Posted:
2014-02-27
First Post:
2010-06-23
Brief Title:
A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive HR Breast Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Epidemiological Prospective Cohort Study to Describe Treatment Patterns of Fulvestrant And ExemeSTane in Postmenopausal Patients With Advanced HR Breast Cancer Under Real-life Conditions in GERmany
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACT-FASTER
Brief Summary:
For patients receiving Faslodex 500 mg to compare the effectiveness in terms of Time to Progression TTP as a function of the line of treatment ie 1st vs 2nd vs 3rd line For all patients to collect and explore real-life data on the epidemiology and management of Pseudomyxoma Peritonea PMP patients with HR advanced breast cancer ABC treated with Faslodex 500 mg or exemestane
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NIS-ODE-FAS-20091 | None | None | None |